Efficacy and Safety of Losartan in Children With Ig A Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02232776|
Recruitment Status : Completed
First Posted : September 5, 2014
Last Update Posted : October 10, 2018
|Condition or disease||Intervention/treatment||Phase|
|Glomerulonephritis, IGA||Drug: Losartan||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||37 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy|
|Study Start Date :||October 2014|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||April 2017|
Experimental: Losartan treatement
All patients had received losartan treatment for 24 weeks.
Dose of Losartan : 0.7mg/kg once daily.
Other Name: Cozaar
- the change in urinary protein-creatinine ratio from baseline to the end of study [ Time Frame: 24weeks ]Change in urinary protein excretion, determined as urinary protein-creatinine ratio compared to baseline, after 24 weeks of treatment.
- the change in urinary albumin-creatinine ratio from baseline to the end of study [ Time Frame: 24 weeks ]Change in urinary albumin-creatinine ratio compared to baseline, after 24 weeks of treatment.
- the proportion of patients wifh more than 50% decrease of urinary protein-creatinine ratio [ Time Frame: 24 weeks ]Number of patients with wifh more than 50% decrease of urinary protein-creatinine ratio compared to baseline, after 24 weeks of treatment.
- the proportion of patients wifh urinary protein-creatinine ratio < 0.2 at the end of study [ Time Frame: 24 weeks ]Number of patients wifh urinary protein-creatinine ratio < 0.2 after 24 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02232776
|Korea, Republic of|
|Seoul National University Children's Hospital|
|Seoul, Korea, Republic of|
|Study Chair:||Hee Gyung Kang, Ph.D||Seoul National University Children's Hospital Departments of Pediatrics|